In this issue of The Oncology Pharmacist, we feature an article on the new—and often misunderstood—world of biosimilars. “They’re new to everyone, and we’re all still trying to figure out what these are, how we’ll deal with them, and how institutions will bring them on board,” explained Jim M. Koeller, MS, Professor, College of Pharmacy, University of Texas at Austin.
We also highlight a recent presentation from the 2016 Multidisciplinary Head and Neck Cancer Symposium, wherein Tanguy Seiwert, MD, Associate Director, Head and Neck Cancer Program, University of Chicago, IL, offered some immunotherapy “pearls” based on his experience from treating a substantial number of patients with immunotherapy.
In addition, this issue provides insight into whether multivitamin use during chemotherapy may reduce the risk for peripheral neuropathy; about an updated survivorship guideline from the National Comprehensive Cancer Network that includes an extensive revision on addressing sexual function in cancer survivors; and regarding the differences between any- and own-occupation disability insurance for pharmacists.
Please visit our website, www.TheOncologyPharmacist.com, to share with us your feedback about this issue. You can also send comments to info@TheOncologyPharmacist.com. We hope you will enjoy this issue, and we look forward to your feedback.
